Combination of fenofibrate and rosiglitazone synergistically ameliorate dyslipidemia and insulin resistance in mice with MSG metabolic syndrome

Yao Xue Xue Bao. 2010 Nov;45(11):1459-66.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 11-beta-Hydroxysteroid Dehydrogenase Type 1 / genetics
  • 11-beta-Hydroxysteroid Dehydrogenase Type 1 / metabolism
  • Adipose Tissue, White / drug effects
  • Animals
  • Animals, Newborn
  • Blood Glucose / metabolism
  • Body Weight / drug effects
  • Drug Synergism
  • Eating / drug effects
  • Fenofibrate / pharmacology*
  • Hypoglycemic Agents / pharmacology
  • Hypolipidemic Agents / pharmacology
  • Insulin Resistance*
  • Lipids / blood
  • Lipoprotein Lipase / genetics
  • Lipoprotein Lipase / metabolism
  • Liver / drug effects
  • Metabolic Syndrome* / chemically induced
  • Metabolic Syndrome* / metabolism
  • Metabolic Syndrome* / pathology
  • Mice
  • Mice, Inbred ICR
  • RNA, Messenger / metabolism
  • Rosiglitazone
  • Sodium Glutamate
  • Thiazolidinediones / pharmacology*

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Hypolipidemic Agents
  • Lipids
  • RNA, Messenger
  • Thiazolidinediones
  • Rosiglitazone
  • 11-beta-Hydroxysteroid Dehydrogenase Type 1
  • Lipoprotein Lipase
  • Fenofibrate
  • Sodium Glutamate